OUR NEWS - RECENT NEWS
The CATALIS Network Rolls Out a New Strategic Plan for 2024-2028
The CATALIS Network Rolls Out a New Strategic Plan for 2024-2028 The CATALIS Quebec Network is pleased to announce the rollout of its new 2024-2028 Strategic Plan in collaboration with its partners, the Ministry of Health and Social Services (MHSS) and the Ministry of Economy, Innovation and Energy (MEIE). An Innovative and Ambitious Strategic Plan for 2024-2028
The CATALIS Network Supports Provincial Efforts for an Even More Innovative and Productive Clinical Research Environment
The CATALIS Network Supports Provincial Efforts for an Even More Innovative and Productive Clinical Research Environment Since its inception, CATALIS Quebec’s government mandate has been to act as a neutral and agile entity for mobilizing and coordinating efforts aimed at optimizing Quebec’s clinical research environment. CATALIS has facilitated more than 280 advisory committees and working groups with members of
3 Pharmaceutical Companies Join the CATALIS Network
3 Pharmaceutical Companies Join the CATALIS Network CATALIS is pleased to welcome the pharmaceutical companies Alexion, Lilly Canada and Novo Nordisk Canada Inc. to its Network of partners. These companies join the many industry partners committed to the Network, namely Abbvie, AstraZeneca, Bayer, BeiGene, Boehringer Ingelheim, Bristol Myers Squibb, Gilead Sciences Canada, GSK, Merck, Novartis, Pfizer, Roche, Sanofi, Takeda,
2 Patient Organizations Join the CATALIS Network
2 Patient Organizations Join the CATALIS Network New organizations join the CATALIS Network: Asthma Canada and Kidney Cancer Canada. They join more than 30 patient organizations and patient partners who represent the patient’s voice within the Network and contribute to CATALIS’ mission of optimizing clinical research in Quebec, in order to accelerate the development of innovative patient care for
The Chaudière-Appalaches Integrated Health and Social Services Centre Authorized a First Clinical Trial in 8.4 Weeks With the FAST TRACK Evaluation Service and Recruited the First Canadian Participant
The Chaudière-Appalaches Integrated Health and Social Services Centre Authorized a First Clinical Trial in 8.4 Weeks With the FAST TRACK Evaluation Service and Recruited the First Canadian Participant The very first collaboration between the Chaudière-Appalaches Centre intégré de santé et de services sociaux (integrated health and social services centre or CISSS) and CATALIS’ FAST TRACK Evaluation Service has been
Bayer: The CHUM Was Ranked First in the World After Using the FAST TRACK Evaluation Service for the First Time
Bayer: The CHUM Was Ranked First in the World After Using the FAST TRACK Evaluation Service for the First Time The Bayer pharmaceutical company used the FAST TRACK Evaluation Service for the first time to accelerate the authorization of its PAnTHA advanced prostate cancer trial at the Centre hospitalier de l’Université de Montréal (CHUM) in 10.4 weeks, with site
A New Brand Identity for the FAST TRACK Evaluation Service
Almost 2 years after its inauguration, the FAST TRACK Evaluation Service is unveiling a new brand identity. Officially launched by the CATALIS Network in September 2022, the FAST TRACK Evaluation Service aims to authorize clinical trials in ≤ 8 weeks. We are pleased to announce that, to date, the service has enabled the authorization of 37 clinical trials conducted by
Pharmaceutical Company Gilead Sciences Canada Joins the CATALIS Network
Pharmaceutical Company Gilead Sciences Canada Joins the CATALIS Network CATALIS is pleased to welcome the pharmaceutical company Gilead Sciences Canada Inc. to its Network of partners. Gilead joins numerous industry partners that are actively involved in the Network: Abbvie, AstraZeneca, Bayer, BeiGene, Boehringer Ingelheim, Bristol Myers Squibb, GSK, Merck, Novartis, Pfizer, Roche, Sanofi, Takeda, and Vertex. These partners support
4 New Patient Organizations Join the CATALIS Network
4 New Patient Organizations Join the CATALIS Network The CATALIS Network keeps growing. Bladder Cancer Canada, and the Canadian Liver Foundation, and Fighting Blindness Canada have joined 3 patient partners and more than 30 patient organizations. Together, they represent the patient’s voice and contribute to CATALIS’ mission, which is to optimize clinical research in Quebec, in order to
The CATALIS Network Draws on the Expertise of 3 Patient Partners
The CATALIS Network Draws on the Expertise of 3 Patient Partners The CATALIS Network is delighted to rely on the support of patient partners Casandra Poitras, Raymond Vles and Catherine Wilhelmy. Catherine Wilhelmy has been a member of the Patient Advisory Committee since its inception, while Casandra Poitras and Raymond Vles are already involved in the Patient Advisory Committee
BeiGene: A First Trial Authorized With a Median Time of 8.1 Weeks
BeiGene: A First Trial Authorized With a Median Time of 8.1 Weeks Thanks to CATALIS’ FAST TRACK Evaluation Service, the BeiGene pharmaceutical company accelerated the authorization for its trial on chronic lymphoid leukemia (BGB-11417-301) in 3 Quebec hospitals with a median time of 8.1 weeks. In fact, the CHU-Sherbrooke authorized the trial in 7.8 weeks and became the first site
GSK Authorized 3 First Trials With a Median Time of 8.4 Weeks and Activated the First Site Globally
GSK Authorized 3 First Trials With a Median Time of 8.4 Weeks and Activated the First Site Globally Thanks to CATALIS’ FAST TRACK Evaluation Service and its participating healthcare institutions, the GlaxoSmithKline Inc. (GSK) pharmaceutical company was able to accelerate the authorization of three clinical trials, with a record median time of 8.4 weeks. The Galaxies 202 trial, which
Launch of Clinical Trials Quebec, Powered by Catalis, in Partnership With the Quebec Government
Launch of Clinical Trials Quebec, Powered by Catalis, in Partnership With the Quebec Government Clinical trials are an essential step in the successful development of any innovative treatment that benefits our society. Yet few people understand their importance. This is why CATALIS Quebec is proud to have coordinated the development of Clinical Trials Quebec (CTQ), a brand-new information and
A New Chair and a New Member of CATALIS Quebec’s Board of Directors
A New Chair and a New Member of CATALIS Quebec’s Board of Directors Since 2017, CATALIS Quebec’s Board of Directors (BOD) has featured experts from Quebec healthcare institutions, pharmaceutical companies, and independent directors. The Board ensures the sound governance of CATALIS and of its strategic direction, in order to implement the execution of common provincial solutions that will accelerate the discovery of innovative treatments for the benefit of the province’s patients. CATALIS is pleased to announce the appointment of Me Jean Groleau as Chair of the Board of Directors
First Pfizer Pharmaceutical Company Trial Authorized With a Median of 8.2 Weeks Using the FAST TRACK Evaluation Service
First Pfizer Pharmaceutical Company Trial Authorized With a Median of 8.2 Weeks Using the FAST TRACK Evaluation Service For the first time, the Pfizer pharmaceutical company used CATALIS’ FAST TRACK Evaluation Service to authorize a complex Phase Ia/Ib oncology clinical trial, meaning a master protocol that includes several sub-studies. In this study, Pfizer is assessing the effectiveness of a
The Personalized Clinical Trial Support Service Welcomes Five New Patient Associations
The Personalized Clinical Trial Support Service Welcomes Five New Patient Associations Clinical Trials Quebec’s Personalized Clinical Trial Support Service, the newest CATALIS initiative, is available to the following five patient associations: Sickle Cell Anemia Association of Quebec, Ovarian Cancer Canada, Save Your Skin Foundation, Parkinson Québec, and Scleroderma Quebec. These new collaborations aim to provide new patient communities and caregivers with free access to simplified and verified information about available
AbCellera Joins the CATALIS Network
AbCellera Joins the CATALIS Network CATALIS is delighted to welcome AbCellera to its Network of Partners. This new pharmaceutical company will strengthen the CATALIS Network by joining the other partners: AbbVie, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb (BMS), GSK, Merck, Novartis, Pfizer, Roche, Sanofi, Takeda, and Vertex. Together, these partners support CATALIS in its mission to optimize the
Provincial Reference Tools: CATALIS Contributed to the Update
Provincial Reference Tools: CATALIS Contributed to the Update To fulfill its government mandate of optimizing Quebec’s clinical research environment and accelerating the development of innovative treatments for patients, CATALIS participated in the update of five provincial reference tools: the Standard Operating Procedures (SOPs) for Research Ethics Boards (REBs), the Statement on Optimizing the Research Contract Negotiation Process, a provincial
Catalis in Support of the Quebec Government’s Policy on Rare Diseases
CATALIS in Support of the Quebec Government’s Policy on Rare Diseases On June 6, the Quebec government unveiled its Politique québécoise pour les maladies rares (Quebec policy on rare diseases – in French only). In Quebec, 700,000 people with rare diseases, half of whom are children, face significant challenges such as errors in diagnosing their disease and the absence
MASter-1 Study: Authorization in 8 Weeks to Explore a New Treatment for an Extremely Rare Disease
MASter-1 Study: Authorization in 8 Weeks to Explore a New Treatment for an Extremely Rare Disease As mentioned in our December 2022 newsletter, CATALIS is proud to support the Quebec government’s Politique québécoise sur les maladies rares (Quebec policy on rare diseases – in French only), namely by allowing studies to be activated more quickly thanks to its FAST
STRENGTH Study: Zolgensma for Children Aged 2 to 12 With Spinal Muscular Atrophy
STRENGTH Study: Zolgensma for Children Aged 2 to 12 With Spinal Muscular Atrophy In October 2021, Minister Dubé announced that Zolgensma, a drug produced by the Novartis pharmaceutical company, was added to the list of drugs offered in Quebec health facilities to treat children under the age of 2 with spinal muscular atrophy. Spinal muscular atrophy is a rare
Astrazeneca and Vertex Join the Catalis Network
Astrazeneca and Vertex Join the Catalis Network CATALIS Quebec is very proud to announce that pharmaceutical companies AstraZeneca and Vertex are joining the CATALIS Network. As new members, they join Abbvie, Bayer, Boehriger Ingelheim, GSK, Merck, Novartis, Pfizer, Roche, Sanofi and Takeda. Together, the partners support CATALIS in its mission to optimize the clinical research environment to accelerate the
NEPTUNUS-2 Study: Sjogren’s Syndrome Clinical Trial Approved in 8 Weeks via CATALIS’ FAST TRACK Evaluation Service
NEPTUNUS-2 Study: Sjogren’s Syndrome Clinical Trial Approved in 8 Weeks via CATALIS’ FAST TRACK Evaluation Service As mentioned in our December 2022 newsletter, CATALIS is proud to announce that its FAST TRACK Evaluation Service continues to allow industry-financed studies to be authorized in record time. In NEPTUNUS-2, a phase III study, Novartis and Dr. Isabelle Fortin are testing the
ONWARDS Study: Authorization in 9 Weeks for Symptomatic Osteoarthritis of the Knee Study via CATALIS’ FAST TRACK Evaluation Service
ONWARDS Study: Authorization in 9 Weeks for Symptomatic Osteoarthritis of the Knee Study via CATALIS’ FAST TRACK Evaluation Service In addition to the 3 rare disease studies, a 4th Novartis study on symptomatic osteoarthritis of the knee was authorized by the Centre hospitalier universitaire de Sherbrooke (CIUSSS de l’Estrie – CHUS) in record time via the CATALIS FAST TRACK